Search Results - "Spratlin, J.L"

6591 POSTER Improved 6-month Survival Rate in Subjects With Prostate Stem Cell Antigen (PSCA) Positive Tumours in a Global, Randomized Phase 2 Trial Comparing Gemcitabine Vs. Gemcitabine + Ags-1c4d4 (asp6182) in Metastatic Pancreatic Cancer (mPC) by Wolpin, B.M, O'Reilly, E.M, Ko, Y.J, Lima, M.S. Rocha, Spratlin, J.L, Macarulla, T, Pezet, D, Hartford, A, Jackson, L.S, Hidalgo, M

Get full text

832TiP - Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial by Abou-Alfa, G.K., Borbath, I., Clarke, S.J., Hitre, E., Louvet, C., Macarulla, T., Oh, D.-Y., Spratlin, J.L., Valle, J.W., Weiss, K.H., Berman, C., Howland, M., Ye, Y., Cho, T., Moran, S., Javle, M.M.

“…Cholangiocarcinoma is the most common biliary tract malignancy with an estimated incidence in Europe of 0.4–1.8/100,000 patients, and approximately…”
Get full text

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial by Abou-Alfa, G.K., Borbath, I., Clarke, S.J., Hitre, E., Louvet, C., Macarulla, T., Oh, D.-Y., Spratlin, J.L., Valle, J.W., Weiss, K.H., Berman, C., Howland, M., Ye, Y., Cho, T., Moran, S., Javle, M.M.

Get full text

Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients? by Abraham, A.G., Joseph, K., Spratlin, J.L., Zebak, S., Alba, V., Iafolla, M., Ghosh, S., Abdelaziz, Z., Lui, A., Paulson, K., Bedard, E., Chua, N., Tankel, K., Koski, S., Scarfe, A., Severin, D., Zhu, X., King, K., Easaw, J.C., Mulder, K.E.

“…To determine the efficacy of preoperative chemoradiotherapy as per the CROSS protocol for oesophageal/gastroesophageal junction cancer (OEGEJC), when expanded…”
Get full text

Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines by Spratlin, J L, Pitts, T M, Kulikowski, G N, Morelli, M P, Tentler, J J, Serkova, N J, Eckhardt, S G

“…To determine the phenotypic effects of belinostat (bel) and bortezomib (bor) against pancreatic cancer (PC) and hepatocellular cancer (HCC) cell lines…”
Get full text

Ramucirumab. Anti-VEGFR-2 human monoclonal antibody, Antiangiogenic by Spratlin, J.L., Mulder, K.E.

Get full text

Ramucirumab. Anti-VEGFR-2 human monoclonal antibody, Antiangiogenic by Spratlin, J.L., Mulder, K.E.

Get full text